161 related articles for article (PubMed ID: 31009141)
21. Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b.
Ogasawara N; Kobayashi M; Akuta N; Kominami Y; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Suzuki F; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Med Virol; 2018 Feb; 90(2):313-319. PubMed ID: 28906010
[TBL] [Abstract][Full Text] [Related]
22. Predictors of functional benefit of hepatitis C therapy in a 'real-life' cohort.
Steinebrunner N; Stein K; Sandig C; Bruckner T; Stremmel W; Pathil A
World J Gastroenterol; 2018 Feb; 24(7):852-861. PubMed ID: 29467555
[TBL] [Abstract][Full Text] [Related]
23. Improvement of liver stiffness measurement, acoustic radiation force impulse measurements, and noninvasive fibrosis markers after direct-acting antivirals for hepatitis C virus G4 recurrence post living donor liver transplantation: Egyptian cohort.
Alem SA; Said M; Anwar I; Abdellatif Z; Elbaz T; Eletreby R; AbouElKhair M; El-Serafy M; Mogawer S; El-Amir M; El-Shazly M; Hosny A; Yosry A
J Med Virol; 2018 Sep; 90(9):1508-1515. PubMed ID: 29718546
[TBL] [Abstract][Full Text] [Related]
24. Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis.
van der Meer AJ; Maan R; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Manns MP; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL
J Gastroenterol Hepatol; 2016 Jun; 31(6):1168-76. PubMed ID: 26647353
[TBL] [Abstract][Full Text] [Related]
25. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
[TBL] [Abstract][Full Text] [Related]
26. Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients.
Mölleken C; Ahrens M; Schlosser A; Dietz J; Eisenacher M; Meyer HE; Schmiegel W; Holmskov U; Sarrazin C; Sorensen GL; Sitek B; Bracht T
Clin Mol Hepatol; 2019 Mar; 25(1):42-51. PubMed ID: 30449076
[TBL] [Abstract][Full Text] [Related]
27. Clinical impact of serum α-fetoprotein and its relation on changes in liver fibrosis in hepatitis C virus patients receiving direct-acting antivirals.
Fouad R; Elsharkawy A; Abdel Alem S; El Kassas M; Alboraie M; Sweedy A; Afify S; Abdellatif Z; Khairy M; Esmat G
Eur J Gastroenterol Hepatol; 2019 Sep; 31(9):1129-1134. PubMed ID: 30896550
[TBL] [Abstract][Full Text] [Related]
28. Effects of HCV Clearance with Direct-Acting Antivirals (DAAs) on Liver Stiffness, Liver Fibrosis Stage and Metabolic/Cellular Parameters.
Ferreira J; Bicho M; Serejo F
Viruses; 2024 Feb; 16(3):. PubMed ID: 38543737
[TBL] [Abstract][Full Text] [Related]
29. Baseline thrombopoietin level is associated with platelet count improvement in thrombocytopenic chronic hepatitis C patients after successful direct-acting antiviral agent therapy.
Chen YC; Ko PH; Lee CC; Tseng CW; Tseng KC
BMC Gastroenterol; 2021 Jan; 21(1):30. PubMed ID: 33478399
[TBL] [Abstract][Full Text] [Related]
30. Serum Galectin-3 in Hepatitis C Virus Infection Declines after Successful Virus Eradication by Direct-Acting Antiviral Therapy.
Weigand K; Peschel G; Grimm J; Müller M; Buechler C
J Gastrointestin Liver Dis; 2022 Dec; 31(4):444-452. PubMed ID: 36535063
[TBL] [Abstract][Full Text] [Related]
31. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
[TBL] [Abstract][Full Text] [Related]
32. Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients.
Mohamed MS; Hanafy AS; Bassiony MAA; Hussein S
Eur J Gastroenterol Hepatol; 2017 Dec; 29(12):1368-1372. PubMed ID: 28953002
[TBL] [Abstract][Full Text] [Related]
33. Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens.
Attia D; Deterding K; Cornberg J; Gebel MJ; Cornberg M; Manns MP; Wedemeyer H; Potthoff A
Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):67-74. PubMed ID: 30239347
[TBL] [Abstract][Full Text] [Related]
34. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
[TBL] [Abstract][Full Text] [Related]
35. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.
Romano A; Angeli P; Piovesan S; Noventa F; Anastassopoulos G; Chemello L; Cavalletto L; Gambato M; Russo FP; Burra P; Vincenzi V; Scotton PG; Panese S; Tempesta D; Bertin T; Carrara M; Carlotto A; Capra F; Carolo G; Scroccaro G; Alberti A
J Hepatol; 2018 Aug; 69(2):345-352. PubMed ID: 29551707
[TBL] [Abstract][Full Text] [Related]
36. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
37. Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis.
Persico M; Rosato V; Aglitti A; Precone D; Corrado M; De Luna A; Morisco F; Camera S; Federico A; Dallio M; Claar E; Caporaso N; Masarone M
Antivir Ther; 2018; 23(2):129-138. PubMed ID: 28799522
[TBL] [Abstract][Full Text] [Related]
38. Effect of Low Positive End of Treatment Viral Load with Direct-Acting Antiviral Therapy on Sustained Virologic Response.
Pal V; Ancha N; Mann J; Modi AA
Can J Gastroenterol Hepatol; 2020; 2020():8815829. PubMed ID: 32802821
[TBL] [Abstract][Full Text] [Related]
39. Long term changes in thrombocytopenia and leucopenia after HCV eradication with direct-acting antivirals.
Tajiri K; Okada K; Ito H; Kawai K; Kashii Y; Tokimitsu Y; Muraishi N; Murayama A; Hayashi Y; Minemura M; Takahara T; Shimizu Y; Yasuda I
BMC Gastroenterol; 2023 May; 23(1):182. PubMed ID: 37231349
[TBL] [Abstract][Full Text] [Related]
40. Impact of CD4+ T-cell count on sustained virologic response to direct-acting antivirals in hepatitis C virus monoinfected cancer patients: a prospective observational study.
Angelidakis G; Pritchard H; Yibirin M; Jiang Y; Mustafayev K; Torres HA
Diagn Microbiol Infect Dis; 2022 Jul; 103(3):115719. PubMed ID: 35605562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
